We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.50 | 18.50 | 18.00 | 18.00 | 18.00 | 66,018 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/3/2019 10:07 | Grow up sunshine. | scotty1 | |
20/3/2019 22:33 | Quite the reverse aspex. That’s why you have a 6% spread, not all are gullible out there! | rayrac | |
20/3/2019 18:05 | That really is some list, Parob. Thanks for keeping tabs as ever. | colinzeal | |
20/3/2019 17:44 | Incredible 6 percent spread at the close with very low turnover just indicates that the broad understanding of today's deal by your average punter is not there. | aspex | |
20/3/2019 17:31 | Updated list following today's deal.Recent, current and potential future revenue streams confirmed:- GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance)- Sacco/CSL - HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical)- Pharmabiota- Galenicum Special Ingredients - Knighton Foods- Cereal Ingredients Inc.- Fine Foods & Pharmaceuticals- Trigen Pharma- Cambridge Commodities - Akums Drugs and Pharma- Seed Health- John Morley's - Alfasigma- Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution.- Unnamed US pharma partner (cholesterol strain)- Bened Biomedical- Bulgarian CholBiome distributor (Velinoff Pharma/Medochem)- CTC Group- Formulation Creations- US Pharma Lab Inc.- Unnamed Greece and Cyprus CholBiome distributor- Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences - SilvExpo - CholBiome- Biolat - RMS CardioPro- EIWA Trading Co. Ltd- DKSHRevenue not confirmed yet:- Tata X 2 (Slimbiome and LPGOS)- Mystery US Slimbiome customer- Paradise Fruits (Slimbiome)- Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL)Products on the market already but not RNSed:- MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic - Aragan - BioticP3- 39ytu - Capsa Food | parob | |
20/3/2019 15:58 | I think the clue is in the rns which reads " market exclusivity is linked to sales orders". | 1bokke | |
20/3/2019 15:08 | Anyone know if it’s just Gofigure or if it also involves Slimbiome Medical for this deal? | imnotlong | |
20/3/2019 14:17 | I asked Stephen O'Hara, CEO of the OptiBiotix, if today's announcement is purely B2c via a B2B partnership, and not related to establishing new products and if so, is it safe to assume revenues, sales should be pretty quick, perhaps as quick as H2 this year? Essentially, this agreement takes GoFigure products to a new much bigger level via a partner that has already established partnerships within the consumer market, meaning the typical 9-12 months each B2B deal takes to establish a product from scratch is not the case because this agreement is for existing SlimBiome products. Stephen O'Hara: "Yes. I have built into the agreement a requirement for orders within the financial year. They are a big company with a big network so should be good." | scotty1 | |
20/3/2019 13:33 | Rayrac so in your opinion best for companies not to do any deal big companies,good logic there NOT | scotty1 | |
20/3/2019 13:31 | Yes seen that over on LSE rafboy Todays London MetroToday 09:58Big Full Page Article on Go Figure - Don't Yo-Yo, give science a go. | scotty1 | |
20/3/2019 13:27 | Another advertorial in METRO today I am told. Not seen myself. | rafboy | |
20/3/2019 13:23 | Another advertorial in METRO today I am told. | rafboy | |
20/3/2019 13:22 | He’s right. Can’t see any logic in the deal for opti...they’ve got Opti by the short and curlies. If Opti got more than 1% out of it, I’d be amazed. | rayrac | |
20/3/2019 12:49 | mike with all due respect you bought in and didn't even know who SoH was/is so not much research there mate 😒 mikethebike4 11 Mar '19 - 17:29 - 47322 of 47591 0 1 0 who is SoH ? | scotty1 | |
20/3/2019 12:22 | Nobbygnome 'This deals highlights the elegant business model. A big deal with just one of the product areas in big countries with a company which is big in those countries. The exponential growth of revenues is bound to follow with this approach.' See Futura Medical (FUM)for a company with the above philosophy and look where it has got them after 17 years You are entirely in the hands of the 'big company' - even if they want to suppress your product for any reason ! - they obviously don't mention this when doing the original deal | mikethebike4 | |
20/3/2019 11:40 | Parob, agreed. The problem we have, is like risky pointed out with my hypothesis, we dont know at what rate revenues per deal are building, until we have an RNS with actual revenue figures we are stuck. I believe it's growing, but the market doesn't like the Adam Reynolds keyboard! | toyin | |
20/3/2019 11:33 | The disconnect between deals/progress and share price won't last forever.All it is going to take is a large deal to break us out of this flag/trading range and we will be away. | parob | |
20/3/2019 11:29 | risky, my £3.75m is looking better by the day!😉 | toyin | |
20/3/2019 11:14 | DKSH in Spain'DKSH Business Line Food & Beverage Industry is a leading food ingredients distributor and global provider of Market Expansion Services for business partners in the beverage, dairy, confectionery and bakery, nutritional supplements, processed food and food service industries.''We develop tailor-made new products, formulations and breakthrough applications in collaboration with our team of specialized staff from our dedicated award-winning innovation centers. Our market insight and broad overview enables us to scout for long-term trends in products and technology beyond short-lived fashions.''We provide all the required marketing and sales services as well as distribution and inbound logistics for companies lacking a global footprint. We have the capability to manage your entire supply chain, including import and export management, warehousing solutions and specialized services, such as labelling and invoicing.'Nice deal with a multi £bn corporate with a proven & established market penetration model. Goes to show what's going on in the background. https://dksh.com/es- | riskybusiness1 | |
20/3/2019 08:22 | Worth notin g this distribution deal includes extg products so time to point of sales and revenues should be pretty fast. I do like the mix of deals and revenues and sales targets set for partners. A little patience when we are so close is all we need. There’s been some notable restlessness here but nows the time to be brave whilst volumes are low and tax year end . April should be a big month imo. S | shrewdmole |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions